BIB Fees and Costs — ProShares Ultra Nasdaq Biotechnology
Data updated: 2026-08-14
The net expense ratio is 0.95%: a 0.75% management fee plus 0.39% other expenses, less a 0.19% fee waiver. There are no sales loads or redemption fees. In fiscal 2026 the fund paid $4K in broker commissions, 0.0063% of average net assets, and portfolio turnover was 32%.
BIB Fees and Expenses
Annual operating expenses and sales charges of BIB. Prospectus, as of March 31, 2025.
| Annual operating expenses | |
|---|---|
| Management fee | 0.75% |
| 12b-1 fee | — |
| Other expenses | 0.39% |
| Gross expense ratio | 1.14% |
| Fee waiver | −0.19% |
| Net expense ratio | 0.95% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | Yes |
BIB Costs Over Time
On $10,000 invested in BIB, assuming 5% a year before costs, total costs come to $599 over 5 years, cutting the return by 1.00% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 0.95%) | $100 | $311 | $540 |
| Trading costs (broker commissions) | $1 | $2 | $4 |
| Lost growth on money paid in costs | $0 | $16 | $55 |
| Total costs | $100 | $329 | $599 |
| Value after costs | $10,400 | $11,247 | $12,164 |
| Impact on return, per year | 1.00% | 1.00% | 1.00% |
BIB Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending May 31, 2026.
- Explicit cost rate (commissions ÷ average net assets): 0.0063%
- Total broker commissions: $4K
- Bought from dealers (principal trades, not a cost): $149.3M
- Portfolio turnover (prospectus): 32%
- Securities on loan, average value: $1.1M
- Net income from securities lending: $28K (0.040% of average net assets)
BIB Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| BNP Paribas Securities Corp. | $3K | 58.21% |
| Susquehanna Financial Group, LLLP | $2K | 41.79% |
BIB Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| J.P. Morgan Securities LLC | $89.2M | 59.77% |
| Merrill Lynch, Pierce, Fenner & Smith Inc. | $25.1M | 16.80% |
| Bank of Montreal | $12.9M | 8.66% |
| Jane Street Capital, LLC | $7.9M | 5.28% |
| Virtu Americas LLC | $5.0M | 3.35% |
| Wells Fargo Securities, LLC | $5.0M | 3.33% |
| Barclays Capital, Inc. | $2.2M | 1.47% |
| Goldman Sachs & Co. LLC | $2.0M | 1.34% |
| BNP Paribas Securities Corp. | $532 | 0.00% |
| Susquehanna Financial Group, LLLP | $432 | 0.00% |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.